Barinthus Biotherapeutics plc (NASDAQ:BRNS – Free Report) – William Blair cut their FY2025 earnings per share estimates for shares of Barinthus Biotherapeutics in a report issued on Wednesday, May 7th. William Blair analyst A. Hsieh now forecasts that the company will post earnings of ($1.63) per share for the year, down from their previous forecast of ($1.52). The consensus estimate for Barinthus Biotherapeutics’ current full-year earnings is ($1.38) per share. William Blair also issued estimates for Barinthus Biotherapeutics’ FY2026 earnings at ($1.69) EPS.
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.15).
Read Our Latest Report on BRNS
Barinthus Biotherapeutics Price Performance
Shares of NASDAQ:BRNS opened at $0.93 on Monday. The business’s 50 day simple moving average is $0.89 and its 200-day simple moving average is $1.01. The firm has a market capitalization of $37.52 million, a price-to-earnings ratio of -0.62 and a beta of -0.80. Barinthus Biotherapeutics has a 12 month low of $0.64 and a 12 month high of $2.44.
Institutional Trading of Barinthus Biotherapeutics
An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. Gilead Sciences Inc. purchased a new position in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics accounts for approximately 0.0% of Gilead Sciences Inc.’s investment portfolio, making the stock its 14th largest position. Gilead Sciences Inc. owned 1.54% of Barinthus Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. 25.20% of the stock is currently owned by institutional investors and hedge funds.
Barinthus Biotherapeutics Company Profile
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
Read More
- Five stocks we like better than Barinthus Biotherapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
- Profitably Trade Stocks at 52-Week Highs
- 4 Automaker Stocks React to Tariffs: Winners and Losers
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Here’s Why Call Option Traders Love Dutch Bros Stock
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.